Glasner-Edwards Suzette, Mooney Larissa J, Marinelli-Casey Patricia, Hillhouse Maureen, Ang Alfonso, Rawson Richard
Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA.
J Subst Abuse Treat. 2008 Dec;35(4):445-50. doi: 10.1016/j.jsat.2007.12.004. Epub 2008 Feb 21.
Little is known about the association between psychosis and treatment outcomes in methamphetamine (MA) users. Using data from 526 adults in the largest psychosocial clinical trial of MA users conducted to date, this study examined psychiatric, substance use, and functional outcomes of MA users with concomitant psychotic illness 3 years after treatment. The presence of a psychotic disorder was associated with increased health service utilization and higher levels of psychiatric symptomatology across multiple domains over time. MA users with co-occurring psychotic illness may therefore benefit from early psychosocial and/or pharmacologic interventions to address psychiatric symptoms.
关于甲基苯丙胺（MA）使用者的精神病与治疗结果之间的关联，目前所知甚少。本研究利用了迄今为止针对MA使用者开展的最大规模社会心理临床试验中526名成年人的数据，对伴有精神病性疾病的MA使用者治疗3年后的精神状况、物质使用情况及功能结局进行了研究。随着时间推移，精神病性障碍的存在与卫生服务利用率增加以及多个领域更高水平的精神症状相关。因此，伴有精神病性疾病的MA使用者可能会从早期社会心理和/或药物干预中受益，以解决精神症状。
